Antipsychotic Agents

• 

  Subject Areas on Research

  • 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. 
  • 49th Annual Meeting of the American Academy of Child & Adolescent Psychiatry. 22-27 October 2002, San Francisco, CA, USA. 
  • A Pharmacy-Based Electronic Handoff Tool to Reduce Discharge Prescribing of Atypical Antipsychotics Initiated in the Intensive Care Unit: A Quality Improvement Initiative. 
  • A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. 
  • A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. 
  • A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. 
  • A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients. 
  • A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). 
  • A new method for studying the interaction between chlorpromazine and phospholipid bilayer. 
  • A perilous disconnect: antipsychotic drug use in very young children. 
  • A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment. 
  • A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. 
  • A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. 
  • A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). 
  • A randomized trial of a consultation service to reduce falls in nursing homes. 
  • A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. 
  • A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia. 
  • A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. 
  • A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. 
  • A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. 
  • A+KIDS, a web-based antipsychotic registry for North Carolina youths: an alternative to prior authorization. 
  • ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. 
  • Acute dystonic reaction with moderate-dose ziprasidone. 
  • Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs. 
  • Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. 
  • Adjunctive brexpiprazole for the treatment of major depressive disorder. 
  • Adjunctive use of olanzapine in mood disorders: five case reports. 
  • Advancing drug discovery for schizophrenia. 
  • Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. 
  • Akt/GSK3 signaling in the action of psychotropic drugs. 
  • Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. 
  • Amisulpride Prevents Postoperative Nausea and Vomiting in Patients at High Risk: A Randomized, Double-blind, Placebo-controlled Trial. 
  • An assessment of the understanding and motivations of patients with schizophrenia about participating in a clinical trial. 
  • An open-label pilot study of aripiprazole for male and female veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants. 
  • An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. 
  • An overview of the clinical rationale for advancing gender-related psychopharmacology and drug abuse research. 
  • An unsubstantiated conclusion. 
  • Angioedema occurring in patient prescribed iloperidone and haloperidol: a cross-sensitivity reaction to antipsychotics from different chemical classes. 
  • Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. 
  • Anticipating DSM-V: opportunities and challenges for cognition and psychosis. 
  • Antipsychotic drug effects on brain morphology in first-episode psychosis. 
  • Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. 
  • Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. 
  • Antipsychotic medications and sudden cardiac death. 
  • Antipsychotic-induced weight gain and therapeutic response: a differential association. 
  • Antipsychotics and dementia: where do we go from here? 
  • Antipsychotics and sudden death: is thioridazine the only bad actor? 
  • Antipsychotics and the risk of sudden cardiac death. 
  • Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome. 
  • Aripiprazole: pharmacology, efficacy, safety and tolerability. 
  • Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. 
  • Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. 
  • Atypical antidopaminergic properties of CI-686: a potential antipsychotic agent. 
  • Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. 
  • Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis. 
  • Atypical antipsychotic drugs and hyperglycemia in adolescents. 
  • Atypical antipsychotics and pituitary neoplasms in the WHO database. 
  • Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. 
  • Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice. 
  • Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents. 
  • Barriers to employment for people with schizophrenia. 
  • Bipolar Depression: Pregnancy, Postpartum, and Lactation. 
  • Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. 
  • Body mass index and future schizophrenia in Israeli male adolescents. 
  • Brain stem as a target site for the metabolic side effects of olanzapine. 
  • Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. 
  • Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial. 
  • COMT158 polymorphism and hostility. 
  • COVID-19-associated brief psychotic disorder. 
  • Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. 
  • Cardiometabolic Assessment, Diagnosis, and Treatment of Chronic Medical Illnesses During an Inpatient Psychiatric Hospitalization: Colocated Medical Care Versus Treatment as Usual. 
  • Case report: possible neuroleptic malignant syndrome associated with olanzapine. 
  • Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics. 
  • Caudate hyperintensities in elderly depressed patients with neuroleptic-induced parkinsonism. 
  • Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. 
  • Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. 
  • Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. 
  • Characteristics of antipsychotic medication prescribing on inpatient obstetric floors. 
  • Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. 
  • Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. 
  • Chronic neuroleptic effects on spatial reversal learning in monkeys. 
  • Chronic neuroleptics alter the effects of the D1 agonist SK&F 38393 and the D2 agonist LY171555 on oral movements in rats. 
  • Chronic nicotine and dizocilpine effects on nicotinic and NMDA glutamatergic receptor regulation: interactions with clozapine actions and attentional performance in rats. 
  • Chronic nicotine interactions with clozapine and risperidone and attentional function in rats. 
  • Chronic underactivity of medial frontal cortical beta2-containing nicotinic receptors increases clozapine-induced working memory impairment in female rats. 
  • Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. 
  • Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. 
  • Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy? 
  • Clozapine treatment reverses dizocilpine-induced deficits of pre-pulse inhibition of tactile startle response. 
  • Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. 
  • Cognition in schizophrenia: summary Nice Consultation Meeting 2012. 
  • Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). 
  • Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. 
  • Cognitive effects of quetiapine XR in patients with euthymic bipolar disorder. 
  • Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. 
  • Cognitive impairment as a target for pharmacological treatment in schizophrenia. 
  • Cognitive impairment in schizophrenia. 
  • Comment on Nasrallah et al: lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol. 
  • Comments on "Addition of lamotrigine to valproic acid: a successful outcome in a case of rapid-cycling bipolar affective disorder". 
  • Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. 
  • Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. 
  • Comparative genomic evidence for the involvement of schizophrenia risk genes in antipsychotic effects. 
  • Comparative mortality risks of antipsychotic medications in community-dwelling older adults. 
  • Comparison of academic and nonacademic sites in multi-center clinical trials. 
  • Comparison of adaptive treatment strategies based on longitudinal outcomes in sequential multiple assignment randomized trials. 
  • Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. 
  • Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study. 
  • Concealed medicines for people with schizophrenia: a U.S. perspective. 
  • Continuation of clozapine during chemotherapy: a case report and review of literature. 
  • Continuity of antipsychotic medication management for Medicaid patients with schizophrenia. 
  • Correlates of Future Violence in People Being Treated for Schizophrenia. 
  • Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. 
  • Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. 
  • Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. 
  • Criminal justice system involvement among people with schizophrenia. 
  • Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. 
  • D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine. 
  • Decision model for the acute treatment of mania. 
  • Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. 
  • Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action. 
  • Delirium in older persons. 
  • Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. 
  • Determination of sulpiride by capillary electrophoresis with end-column electrogenerated chemiluminescence detection. 
  • Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. 
  • Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. 
  • Difficult behaviors in long-term care patients with dementia. 
  • Difficult behaviors in long-term care patients with dementia. 
  • Discharge Plans for Geriatric Inpatients with Delirium: A Plan to Stop Antipsychotics? 
  • Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. 
  • Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. 
  • Does sigma receptor antagonism predict clinical antipsychotic efficacy? 
  • Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. 
  • Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. 
  • Drug and alcohol trajectories among adults with schizophrenia: data from the CATIE study. 
  • Drugs of the psychopharmacological revolution in clinical psychiatry. 
  • Dual Health Care System Use and High-Risk Prescribing in Patients With Dementia: A National Cohort Study. 
  • Dual Health Care System Use and Unsafe Medication Prescribing in Veterans With Dementia. 
  • Dynamics of lip dyskinesia associated with neuroleptic withdrawal. 
  • Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. 
  • Eating disorders. 
  • Effect of Medicaid Policy Changes on Medication Adherence: Differences by Baseline Adherence. 
  • Effect of a mental health "carve-out" program on the continuity of antipsychotic therapy. 
  • Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. 
  • Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. 
  • Effectiveness of atypical antipsychotics for substance use in schizophrenia patients. 
  • Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. 
  • Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. 
  • Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. 
  • Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. 
  • Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. 
  • Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. 
  • Effectiveness of switching from antipsychotic polypharmacy to monotherapy. 
  • Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. 
  • Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. 
  • Effects of amphetamines and small related molecules on recovery after stroke in animals and man. 
  • Effects of antipsychotic medication on psychiatric service utilization and cost. 
  • Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. 
  • Effects of antipsychotic medications on sleep in schizophrenia. 
  • Effects of antipsychotic withdrawal in elderly nursing home residents. 
  • Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. 
  • Effects of classical and atypical antipsychotic drugs on isolation-induced aggression in male mice. 
  • Effects of clozapine on memory function in the rat neonatal hippocampal lesion model of schizophrenia. 
  • Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. 
  • Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. 
  • Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness. 
  • Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. 
  • Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. 
  • Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice. 
  • Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. 
  • Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. 
  • Efficacy of olanzapine in social anxiety disorder: a pilot study. 
  • Efficacy of risperidone on positive features of schizophrenia. 
  • Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale. 
  • Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. 
  • Estimating suicidality as an outcome measure in clinical trials of suicide in schizophrenia. 
  • Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial. 
  • Evaluation of the effects of diazepam and an experimental anti-anxiety drug on regional cerebral blood flow. 
  • Examination of QTc Values in Critically Ill Patients Diagnosed with Delirium and Prescribed Atypical Antipsychotics. 
  • Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol. 
  • Examining Parental Medication Adherence as a Predictor of Child Medication Adherence in Pediatric Anxiety Disorders. 
  • Examining the relationship between adjunctive psychotherapy use and antipsychotic persistence and hospitalization. 
  • Extrapyramidal side-effects of antipsychotics in a randomised trial. 
  • Feasibility of myelosuppressive chemotherapy in psychiatric patients on clozapine: A systematic review of the literature. 
  • First- and second-generation antipsychotics. 
  • First-line pharmacotherapy approaches for generalized anxiety disorder. 
  • Frequency of high-risk use of QT-prolonging medications. 
  • GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder. 
  • Genetic correlates of insight in schizophrenia. 
  • Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. 
  • Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. 
  • Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. 
  • Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. 
  • Haase hermeneutics, or, the exegesis of the neuroleptic threshold. 
  • Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications. 
  • High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. 
  • Histamine H1 receptor involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of clozapine. 
  • Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia. 
  • IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness. 
  • Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. 
  • Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. 
  • Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. 
  • Impact of neuroleptic medications on continuous performance test measures in schizophrenia. 
  • Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. 
  • Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. 
  • Implications of atypical antipsychotic prescribing in the intensive care unit. 
  • In Vitro and In Vivo Characterization of the Alkaloid Nuciferine. 
  • Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. 
  • Inpatient and outpatient patterns of psychotropic drug prescribing by nonpsychiatrist physicians. 
  • Insight in first-episode psychosis. 
  • Integrated approaches to understanding antipsychotic drug action at GPCRs. 
  • Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol. 
  • International prescribing patterns for mood illness: the International Mood Network (IMN). 
  • Intravenous ziprasidone for treatment of delirium in the intensive care unit. 
  • Introduction to the CATIE special section. 
  • Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. 
  • Kraepelinian schizophrenia: a subgroup of schizophrenia? 
  • L-dopa challenge and relapse in schizophrenia. 
  • Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. 
  • Latent class analysis of discordance between results of drug use assessments in the CATIE data. 
  • Lefetamine: new abuse of an old drug--clinical evaluation of opioid activity. 
  • Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. 
  • Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. 
  • Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. 
  • Looking at lithium: molecular moods and complex behaviour. 
  • Measurements of plasma homovanillic acid in schizophrenic patients. 
  • Measuring outcome priorities and preferences in people with schizophrenia. 
  • Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. 
  • Medication compliance. 
  • Medication nonadherence and substance abuse in psychotic disorders: impact of depressive symptoms and social stability. 
  • Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. 
  • Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. 
  • Metabolic profiling of patients with schizophrenia. 
  • Metabolomic mapping of atypical antipsychotic effects in schizophrenia. 
  • Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. 
  • Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders. 
  • Methodological issues in negative symptom trials. 
  • Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. 
  • Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. 
  • Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis. 
  • N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement. 
  • N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. 
  • Neurobiochemical changes in tardive dyskinesia. 
  • Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. 
  • Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. 
  • Neuroleptic treatment and caudate plasticity. 
  • Neuroleptic-induced oral movements in rats: methodological issues. 
  • Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. 
  • New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy. 
  • New Developments in Insomnia Medications of Relevance to Mental Health Disorders. 
  • Nicotine and clozapine actions on pre-pulse inhibition deficits caused by N-methyl-D-aspartate (NMDA) glutamatergic receptor blockade. 
  • Nicotine and clozapine effects on attentional performance impaired by the NMDA antagonist dizocilpine in female rats. 
  • Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. 
  • Nicotine-antipsychotic drug interactions and attentional performance in female rats. 
  • Nicotine-haloperidol interactions and cognitive performance in schizophrenics. 
  • Nicotinic antagonist effects in the mediodorsal thalamic nucleus: regional heterogeneity of nicotinic receptor involvement in cognitive function. 
  • Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. 
  • Nicotinic-antipsychotic drug interactions and cognitive function. 
  • Obesity among those with mental disorders: a National Institute of Mental Health meeting report. 
  • Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. 
  • Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. 
  • Olanzapine and haloperidol in first episode psychosis: two-year data. 
  • Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. 
  • Olanzapine interactions with nicotine and mecamylamine in rats: effects on memory function. 
  • Olanzapine on trial. 
  • Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose. 
  • Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature. 
  • On sample size calculation based on odds ratio in clinical trials. 
  • One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. 
  • Onset of dyskinesia and changes in postural task performance during the course of neuroleptic withdrawal. 
  • Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. 
  • Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents. 
  • Optimizing outcome with antipsychotic treatment in first-episode schizophrenia: balancing efficacy and side effects. 
  • PCM1 is necessary for focal ciliary integrity and is a candidate for severe schizophrenia. 
  • PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. 
  • Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. 
  • Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment. 
  • Patterns of pharmacotherapy and treatment response in elderly adults with bipolar disorder. 
  • Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. 
  • Performance of a weight-related measure of Quality of Life in a psychiatric sample. 
  • Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. 
  • Pharmacologic Intervention for the Treatment and Prevention of Delirium: Looking Beneath the Modeling. 
  • Pharmacologic treatment of posttraumatic stress disorder: a focus on antipsychotic use. 
  • Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. 
  • Pharmacological studies of a novel dopamine-sensitive receptor mediating burst-firing inhibition of neurosecretory cell R 15 in Aplysia californica. 
  • Pharmacometabolomic signature of ataxia SCA1 mouse model and lithium effects. 
  • Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. 
  • Pharmacotherapy of bipolar disorder in old age: review and recommendations. 
  • Pharmacotherapy of impaired affect in recovering schizophrenic patients. 
  • Pharmacotherapy of the Preschool ADHD Treatment Study (PATS) Children Growing Up. 
  • Pharmacovigilance in the 21st century: new systematic tools for an old problem. 
  • Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. 
  • Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. 
  • Post-traumatic stress disorder: an evaluation of existing pharmacotherapies and new strategies. 
  • Predicting antipsychotic use in children. 
  • Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. 
  • Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. 
  • Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. 
  • Predictors of antipsychotic withdrawal or dose reduction in a randomized controlled trial of provider education. 
  • Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. 
  • Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. 
  • Premorbid behavioral and intellectual functioning in schizophrenia patients with poor response to treatment with antipsychotic drugs. 
  • Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. 
  • Prevalence of baseline lipid monitoring in patients prescribed second-generation antipsychotics during their index hospitalization: a retrospective cohort study. 
  • Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population. 
  • Prioritization of research addressing antipsychotics for adolescents and young adults with bipolar disorder. 
  • Progress in delirium. 
  • Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. 
  • Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. 
  • Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. 
  • Providers' Behaviors and Beliefs on Prescribing Antipsychotic Medication to Children: A Qualitative Study. 
  • Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment. 
  • Psychopharmacological treatment for very young children: contexts and guidelines. 
  • Psychotic disorder in a patient with central and extrapontine myelinolysis. 
  • Psychotropic drug use in late life: a diverse look at an expanding field. 
  • Psychotropic drugs on general medical and surgical wards of a teaching hospital. 
  • QTc monitoring in adults with medical and psychiatric comorbidities: Expert consensus from the Association of Medicine and Psychiatry. 
  • Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. 
  • Quetiapine XR: current status for the treatment of major depressive disorder. 
  • Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. 
  • Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. 
  • Quetiapine for the treatment of delirium. 
  • Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. 
  • Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. 
  • Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia. 
  • Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. 
  • Reducing antipsychotic drug prescribing for nursing home patients: a controlled trial of the effect of an educational visit. 
  • Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. 
  • Relating Intrinsic Low-Frequency BOLD Cortical Oscillations to Cognition in Schizophrenia. 
  • Relationship of cognition and psychopathology to functional impairment in schizophrenia. 
  • Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. 
  • Reliabilities and intercorrelations of reported and objective measures of smoking in patients with schizophrenia. 
  • Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale. 
  • Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. 
  • Reproducibility probability in clinical trials. 
  • Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relatives. 
  • Results of phase 3 of the CATIE schizophrenia trial. 
  • Reversal of clozapine effects on working memory in rats with fimbria-fornix lesions. 
  • Revised PORT recommendations. 
  • Risks versus benefits of different types of long-acting injectable antipsychotics. 
  • Risperidone and cognitive function in children with disruptive behavior disorders. 
  • Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. 
  • Risperidone use in autism spectrum disorders: a retrospective review of a clinic-referred patient population. 
  • Risperidone-associated diabetes mellitus: a pharmacovigilance study. 
  • Safety and antipsychotic efficacy of "forced" intramuscular olanzapine over five days: a case report. 
  • Schizophrenia, drug therapy, and monitoring. 
  • Scopolamine interactions with D1 and D2 antagonists on radial-arm maze performance in rats. 
  • Seizure threshold in electroconvulsive therapy: I. Initial seizure threshold. 
  • Separation of promethazine and thioridazine using capillary electrophoresis with end-column amperometric detection. 
  • Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol. 
  • Sleep therapeutics and neuropsychiatric illness. 
  • Smoking and therapeutic response to clozapine in patients with schizophrenia. 
  • Social support in late life mania: GERI-BD. 
  • Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications. 
  • Spine pruning drives antipsychotic-sensitive locomotion via circuit control of striatal dopamine. 
  • Spirituality and religion in outpatients with schizophrenia: a multi-site comparative study of Switzerland, Canada, and the United States. 
  • Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists. 
  • Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. 
  • Substance use and schizophrenia: adverse correlates in the CATIE study sample. 
  • Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. 
  • Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. 
  • Suicide attempts in veterans with bipolar disorder during treatment with lithium, divalproex, and atypical antipsychotics. 
  • Suicide risk analysis among patients assigned to psychotropics and placebo. 
  • Supportive approaches for Alzheimer disease. 
  • Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. 
  • Symptom exacerbation in psychotically depressed adolescents due to high desipramine plasma concentrations. 
  • Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. 
  • Temporal lobe volume in bipolar disorder: relationship with diagnosis and antipsychotic medication use. 
  • The Akt-GSK-3 signaling cascade in the actions of dopamine. 
  • The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. 
  • The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. 
  • The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? 
  • The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. 
  • The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. 
  • The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. 
  • The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. 
  • The Treatment of Behavioral and Psychological Symptoms of Dementia: Weighing Benefits and Risks. 
  • The association between weight change and symptom reduction in the CATIE schizophrenia trial. 
  • The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. 
  • The changing effector pattern of tardive dyskinesia during the course of neuroleptic withdrawal. 
  • The changing perspective on chronic insomnia management. 
  • The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. 
  • The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. 
  • The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression. 
  • The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. 
  • The effects of medications on bone. 
  • The effects of race and criminal justice involvement on access to atypical antipsychotic medications among persons with schizophrenia. 
  • The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. 
  • The first clinical study of BW-234U in schizophrenia. 
  • The impact of evidence-based education on prescribing in a psychiatry residency. 
  • The impact of neuroleptic medication on tardive dyskinesia: a meta-analysis of published studies. 
  • The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia. 
  • The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. 
  • The ketogenic diet and remission of psychotic symptoms in schizophrenia: Two case studies. 
  • The pharmacologic management of insomnia in patients with HIV. 
  • The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome. 
  • The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations. 
  • The sleep effects of lurasidone: a placebo-controlled cross-over study using a 4-h phase-advance model of transient insomnia. 
  • The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. 
  • Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. 
  • Time-lapse mapping of cortical changes in schizophrenia with different treatments. 
  • Top Ten Tips Palliative Care Clinicians Should Know About Mental Health and Serious Illness. 
  • Treatment of thyrotoxicosis-induced psychosis. 
  • Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. 
  • Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. 
  • Tremorous mouth movements in rats administered chronic neuroleptics. 
  • Unirhinal olfactory function in schizophrenia patients and first-degree relatives. 
  • Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia. 
  • Use of aripiprazole in a patient with multiple sclerosis presenting with paranoid psychosis. 
  • Use of lamotrigine in a patient with a clozapine-related seizure. 
  • Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. 
  • Ventral hippocampal alpha7 and alpha4beta2 nicotinic receptor blockade and clozapine effects on memory in female rats. 
  • What CATIE found: results from the schizophrenia trial. 
  • Who are the new users of antipsychotic medications? 
  • Working memory and schizophrenia: evidence for slowed encoding. 
  • Ziprasidone-associated mania: a case series and review of the mechanism. 
  • [Problem of neuronal reception and the dopamine hypothesis of schizophrenia]. 
• 

  Keywords of People

  • Bradford, Daniel William, Professor of Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Social and Community Psychiatry
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • Olsen, Maren Karine, Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Wu, Li-Tzy, Professor in Psychiatry and Behavioral Sciences, Medicine, General Internal Medicine